3 Futuristic Health Sensors That Could Save Lives – Fortune

Entrepreneurs at Fortune’s Brainstorm Health conference in San Diego on Wednesday showed off what they believe is the solution to lowering medical costs and bringing better care to the developing world.

They demonstrated a range of devices: a mobile ultrasound machine, a handheld air sensor, and a patient identification necklace. That technology all shared some commonalities including low-cost sensors, wireless connections, and data stored in the cloud.

The devices are intended to be low cost enough that they could be available to patients in the developing world like China, India, and Africa. They may also signal the possible future in more developed countries for more distributed and personalized medicine.

Here’s what the entrepreneurs highlighted:

Handheld Ultrasound:

Qualcomm director Angela Baker and Trice Imaging’s CEO Åsa Nordgren showed off a mobile ultrasound machine and program that has been helping prevent problems for pregnant women in Morocco.

Three hundred thousand women die annually from avoidable pregnancy problems, said Baker and Nordgren. The duo’s “Mobile Ultrasound Patrol” gave provided ultrasound examinations to hundreds of women in small rural Moroccan clinics and were able to reduce the cost of an ultrasound from $80 to $2 per patient.

Mobile Air Sensor:

TZOA is a company that makes sensors that collect information about air quality, including the kinds of particles, the quantity, and if hazardous chemicals are among them. TZOA CEO Kevin Hart said that the company has proven that the gadget is cheaper than sensors used by government agencies for monitoring air quality in cities.

Hart said the devices could be an important way to protect people from pollutants that could impact brain development in fetuses and children. This “builds the case for why clean air matters,” said Hart.

In the future, the company plans to sell its units in China and India for outdoor pollution and the U.S. for indoor pollution. The company is also working on a device for asthmatics that can help determine what lead to an asthmatic attack.

Better Patient IDs:

Ruchit Nagar, CEO of Khushi Baby, said millions of young children die annually from diseases that are preventable with vaccines. One of the issues is that health workers in rural and developing areas don’t have adequate ways to track vaccine needs and schedules for children.

Khushi Baby, which means “happy baby” in Hindi, is developing a wearable medical history necklace that health care workers can read with a basic cell phone app. The necklace uses low power wireless technology that requires no battery and is durable and water proof. Nagar intends to sell the device to governments like India’s health ministries.


Low-cost airline backed by Ryanair opens in Peru – Peru Reports

VivaColombia, a low-cost airline launched by the Ryan family’s Irelandia Aviation, has opened a subsidiary in Peru called Viva Air.

Launched in 2012, VivaColombia was Irelandia’s first foray into South America. The holding company which owns Ryanair and Allegiant airlines had launched VivaAerobus in Mexico six years prior. Based in Medellin instead of Colombia’s capital of Bogota, the airline quickly grew to 16 cities including 12 in Colombia as well as Lima, Miami, Quito and Panama City.

VivaColombia began offering flights between Bogota and Lima in December 2014 three days per week, which increased to five days after one year and now six. Last week the company announced it would introduce domestic routes within Peru in the first quarter of 2017.

At a press conference today in Lima attended by trade and tourism minister Eduardo Ferreyros and PromPeru director Maria Soledad, company officials announced the launch of Viva Air Peru, a new airline with a distinct brand and website.

Peruvian subsidiary director Jose Castellanos said the company would aim to offer flights on many routes for $18 after taxes, representing a 50% discount on current market fares. The airline will initially serve seven cities in Lima, Cusco, Arequipa, Trujillo, Chiclayo, Piura, Iquitos and Tarapoto.

The press conference began with some confusion as a government presenter unsure of the new company’s name and how Viva Colombia fit in was prompted by a company official with “Viva Air Peru.” The website domain is VivaAir.com while the Facebook page is titled “Viva Air Peru.”

Ryanair pioneered a new low-cost airline model which went beyond the cost-cutting gusto of Southwest Airlines with a no-frills service which charges for everything from on-flight beverages to printing a boarding pass.

The model has disrupted the airline industries of Europe and North America as new competitors such as Spirit Airlines have emerged and traditional airlines have begun to charge for services which were previously free.

The news comes just after Declan Ryan, Irelandia Aviation chairman and son of Ryanair founder Tony Ryan, announced the company would sell its stake in its Mexican subsidiary, VivaAerobus.

“We’ve been in Mexico 10 years, we adore the country … But we think the new frontier is the whole of central and South America, and that’s what we’re concentrating on,” Ryan told the Financial Times. “To be frank, the Viva brand could be throughout South America … Viva won’t be as big as Ryanair because the access to disposable income is not the same, but I have no doubt the brand can go to 100 airports.”

Ryan added that he believes the region could support five national airlines and that his next market would likely be Argentina.

VivaColombia became the 21st airline to operate in Peru after three new additions in Interjet, Plus Ultra and British Airways entered the market in the last year. Viva Air Peru will be the first low-cost airline to operate domestic flights in Peru.


Viva Air Peru (Facebook)

Las tarifas a Lima se reducen hasta un 58% con la llegada de VivaColombia (VivaColombia)

VivaColombia iniciará vuelos Lima–Bogotá el 2 de diciembre y cobrará US$ 209 (Gestion)

Aerolínea mexicana Interjet iniciará operaciones hacia Perú a mediados de año (Gestion)

Llega aerolínea low cost y ofrece pasajes a S/60 por tramo (El Comercio)

VivaColombia operará vuelos domésticos en Perú desde primer trimestre del 2017 (Portal de Turismo)

Ryanair co-founder Declan Ryan to sell stake in Mexican carrier (Irish Times)


Low-Cost Housing Projects Will Have to Earmark Cash for Minority and Women Contractors – Observer

Mayor Bill de Blasio announces a new vision for the city's MWBE program, with his senior MWBE adviser, Rev. Jonnel Doris, behind him.

Mayor Bill de Blasio announces a new vision for the city’s MWBE program, with his senior MWBE adviser, Rev. Jonnel Doris, behind him. (Madina Toure/Observer)

Starting next year, affordable housing developers will be required to commit at least 25 percent of the subsidy they receive from the city’s Department of Housing Preservation and Development to certified minority and women-owned business enterprises—a new effort the city says aims to increase the participation of MWBEs in affordable housing development.

Beginning on Jan. 1, affordable housing developments constructed on public land valued at a minimum of $2 million or receiving at least $2 million in city capital will have to participate in the MWBE Design & Build program. The 25 percent requirement applies to the design and construction phase of projects subsidized by HPD.

The city’s MWBE procurement requirements—Mayor Bill de Blasio recently announced a new 30 percent MWBE participation goal to bet achieved by 2021—do not apply to HPD’s affordable housing projects.

“This new program will ensure that more MWBEs can expand their pipelines and build their capacity while providing quality affordable housing for New Yorkers across our city,” HPD Commissioner Vicki Been said in a statement to the Observer. “We look forward to working with our many partners to strengthen the pool of M/WBEs participating in all our efforts to build a more diverse and equitable city.”

All payments to certified MWBEs performing construction or offering professional services will meet the requirement. Developers who do not fulfill the stipulation but do attempt to  identify, reach out to and hire MWBE contractors—including by contacting the Department of Small Business Services and advertising opportunities widely—will be charged with a penalty in the form of liquidated damages. The penalty will be based on a number of factors, including how much of the MWBE participation goal the developer met.

The agency said it would link developers with MWBEs, share pre-qualified lists created by a variety of city agencies and hold networking activities.

Juliet Pierre-Antoine, deputy press secretary for HPD, said there were some projects and developers who went above and beyond to provide opportunities to MWBEs while some did not.

“The truth of the matter is this is a requirement, but the fundamental goal is to expand business ventures for MWBEs so we wanna make sure that they meet this requirement,” Pierre-Antoine said in an interview.

After HPD announced the Housing New York plan—which aims to create 80,000 below-market housing units over 10 years—it launched the Building Opportunities initiative in which it formulated a pre-qualified list of MWBE developers and issued a Request for Proposals for six development sites open exclusively to MWBEs on that list. The agency also said it is working with partners to provide professional development, networking and mentoring programs for MWBE developers through low-cost financing options.

And more than 50 firms have participated in the agency’s Building Capacity Course since it launched in 2014, a course that offers gives MWBE and nonprofit developers in affordable housing development guidance on issues such as site selection, project financing, construction and property management.

The announcement comes on the heels of the release of Comptroller Scott Stringer’s annual MWBE report card for fiscal year 2016. He gave the city a grade of D+ for the second year in a row, saying that out of $15.3 billion the city spent on goods and services, only 4.8 percent went to MWBEs.

But HPD was the only agency to receive an A for the second year in a row (Stringer gave the agency a D for fiscal year 2014.) 

At the end of September, de Blasio announced a new vision for the city’s MWBE program. That included the appointment of Deputy Mayor of Strategic Initiatives Richard Buery as the city’s new MWBE director, the new 30 percent MWBE participation goal and a new MWBE office. The mayor appointed Rev. Jonnel Doris as the city’s senior MWBE adviser in July.

Buery asserted Stringer’s statistics were inaccurate, and noted that the de Blasio administration awarded $697 million in contracts to MWBEs—a 52 percent increase in dollars from the previous year. Buery also said contracts went to MWBEs 14 percent of the time, compared to 8 percent the prior year and that the city is on track to meet its 30 percent goal. 


Low-cost Strategies for Medical Practice Compliance – Diagnostic Imaging

From HIPAA to Occupational Safety and Hazard Administration (OSHA) guidelines, medical practices often face challenges when it comes to compliance, but there are low-cost tips to avoid violations.

That’s according to Marcia L. Brauchler, president of health care consulting firm Physicians’ Ally. Brauchler was a speaker at this year’s Medical Group Management Association (MGMA) Annual Conference in San Francisco.

She shared the results of an informal survey done by her company which indicated that 80 percent of medical practices in the Denver area have a compliance officer. Almost 40 percent said they had no annual budget for compliance. Of the practices that had a budget, it ranged between $200 and $4,000 dollars; or an average of $1,215 per practice.

Brauchler said these statistics show that there is a need for low-cost solutions among medical practices.

The first resource she recommended is the Office of Inspector General (OIG) Individual and Small Group Voluntary Compliance Plan which has been available since 2000. Brauchler pointed out that about half of the survey participants were aware of this resource which is a good starting point.

Marcia L. BrauchlerMarcia L. Brauchler

“OIG, which is the police force for a lot of different federal laws, expects your compliance plan to have at least what has been outlined in this voluntary compliance plan guidance,” she said.

There are OIG Model Compliance Plans for different healthcare entities and Brauchler suggested that medical practices review the “Individual and Small Group Physicians Practices” and “Third Party Medical Billing Companies” plans.

According to the OIG, any compliance program should have seven basic elements, explained Brauchler.

  • It should have written policies and procedures.
  • There should be a designated compliance officer or contact(s).
  • The practice should have a training and education program for staff; for example OSHA requires training upon hire and annually after that and HIPAA requires training upon hire and whenever there is a change in HIPAA law.
  • There should be effective lines of communication so the person who is responsible for the compliance plan should not get squashed by the CEO or someone who does not want to listen.
  • The plan should require internal monitoring or doing your own auditing which includes the three Cs; auditing your care, contracts, and coding.
  • Also, standards need to be enforced; for example if a staff member is in violation of regulations there should be a plan for escalating things from a verbal warning to potential termination.
  • Prompt responses are important since some laws require action within 60 days, so sitting on a violation could get you into trouble.

An informal eighth step, Brauchler noted, is implementation and making sure you catch things before you get caught by an outside entity

“The government wants you to know that ‘I didn’t know this federal law existed’ is no longer an excuse,” said Brauchler.

In fact, OIG recognizes “deliberate ignorance,” and in some cases a penalty is increased if someone at a medical practice is intentionally disregarding guidelines.

“It’s better to try and fail than to not even try to figure out what are rules are,” said Brauchler.


Ryanair plants new low-cost foothold in Frankfurt – Yahoo Sports

Frankfurt (AFP) – Irish low-cost airline Ryanair on Wednesday said it would base two aircraft at Frankfurt airport, Germany’s busiest, serving sun-soaked tourist destinations in Portugal and Spain — sparking outrage among German competitors.

Ryanair hopes to bring 400,000 travellers per year from the German financial centre to Alicante, Faro, Malaga and Palma de Mallorca with 28 flights per week starting in March 2017, Ryanair chief commercial officer David O’Brien said in a statement.

O’Brien said the new base represented an investment of around $200 million (180 million euros).

The move “underlines the increasing importance of Frankfurt for low cost traffic,” Stefan Schulte, chief executive of airport operator Fraport said in the joint statement.

Ryanair will count nine bases in Germany once Frankfurt is up and running, among some 85 in Europe.

Until now, it has only flown to Hahn airport more than 100 kilometres (60 miles) away on the Main River.

Like its peers, the no-frills carrier has avoided Frankfurt due to the high fees charged by Fraport, which mostly serves higher-end airlines.

The only low-cost operators currently flying to the hub are Iceland’s WOW and Spanish Vueling, which between them account for around four percent of traffic, a Fraport spokesman told AFP.

Eurowings, the low-cost subsidiary of German aviation giant Lufthansa, has also stayed away from Frankfurt.

German airline federation BDF released a statement Wednesday blasting a new fee structure Fraport plans to roll out from January that will offer newly-arrived airlines a 40-percent discount compared with existing operators.

“We can’t accept that competitors get the red carpet rolled out with unfair advantages, while those who have for many years been paying for Frankfurt’s infrastructure to be built up with high fees pick up the tab,” said BDF director Michael Engel.

Lufthansa CEO Carsten Spohr, Fraport’s biggest client, on Wednesday demanded a discount equivalent to that on offer to Ryanair, news agency DPA reported.


New, low-cost device measures early stages of infant malnutrition – News-Medical.net

Babies worldwide could benefit from a low-cost device designed by University of Sydney researchers to measures early stages of infant malnutrition.

A team jointly led by Dr Alistair McEwan, an electrical and information technologies engineer at the University, and honorary Professor Heather Jeffery, a specialist in maternal and child health, are conducting successful trials of the device in Soweto, Africa.

Designs of the revolutionary malnutrition screening device have been published today in the journal Scientific Reports.

The unit developed by the team uses near infrared (NIR) to assess an infant’s body composition and is suitable for use in areas where there is limited electricity supply and technical expertise.

Dr McEwan said:

The portable and easy-to-use device uses light to measure the amount of fat under the skin so that infants don’t need to be placed in a scanner or have a skin pinch test.

The device can be made inexpensively with only five sensors and the length or height of the infant does not need to be measured, avoiding a difficult measurement of infants who wriggle and protest at being held flat.

Light in the NIR range is used where our skin is transparent; this type of light is not visible to humans for example on a TV remote control, but can be sensed by nocturnal animals and snakes.

Dr McEwan explains:

NIR is a highly accurate technology that uses multiple wavelengths to separate a human’s body components such as temperature, melanin, water, dermis, muscle or fat under the skin.

The human skin is transparent in NIR light over a certain range of wavelengths. Our studies have shown that fat absorbs NIR and fat levels can be determined at five wavelengths.

Professor Heather Jeffery said:

Low fat composition in newborns exposes them to an immediate risk of increased mortality and morbidity, and to diabetes and obesity diseases in later life.

“The lack of convenient, low-cost devices for monitoring nutrition has led to difficulties for health workers trying to identify malnourished infants, and in monitoring changes in the nutritional status of an infant who has received interventions,” she says.

The team that also included early career researchers Dr Angela Carberry, Dr Peter Jones and PhD candidates Jacqueline Huvanandana and Fatin Hamimi Mustafa, are working alongside the University of Oxford’s INTERBIO-21st study to test their prototype device for suitability in different skin tones and in large communities in Africa.

Dr McEwan oversees the University of Sydney’s bioelectronics program, combining electrical engineering and biology to make inexpensive physiological monitors that reduce the strain on public health budgets.


Verastem Takes a Low-Cost Flier on Infinity’s Blood Cancer Drug – Xconomy


Boston — 

It wasn’t too long ago that a blood cancer drug from Infinity Pharmaceuticals was worth an up front, $275 million from AbbVie. But two years and some disappointing trial results later, Verastem has scooped it up at a fraction of the cost.

Verastem (NASDAQ: VSTM), a Boston company developing stem cell drugs for cancer, has grabbed worldwide rights to duvelisib, a drug Infinity (NASDAQ: INFI) has been advancing as a treatment for a variety of lymphomas. Verastem isn’t paying anything to Infinity up front for the right to duvelisib. Rather, Cambridge, MA-based Infinity will only get $6 million if the drug succeeds in an ongoing Phase 3 trial in chronic lymphocytic leukemia and another $22 million upon the drug’s first regulatory approval. If that happens, Infinity would also get royalties on net sales.

The Phase 3 trial, called DUO, is expected to produce data in the first half of 2017.

The tiny deal terms are not just indicative of Infinity’s struggles with duvelisib, but an indication of the declining interest in drugs that inhibit PI3 kinases, which were a hot field in biology not too long ago. Targets in the PI3 kinase pathway are implicated in a bunch of important molecular functions, like cell survival and proliferation, which is why a bunch of PI3 kinase blockers have been developed for cancer. The first generation of PI3 kinase drugs blocked the whole pathway, leading to a number of unwanted side effects, but more recent drugs, like Gilead Sciences’ (NASDAQ: GILD) idelalisib (Zydelig), and Infinity’s duvelisib, were developed more selectively—to hit certain variations of PI3 kinase instead.

Gilead paid $375 million up front for Calistoga Pharmaceuticals in 2011 to get its hands on idelalisib (Zydelig), and won FDA approval of the drug three years later.  That year, AbbVie (NYSE: ABBV) paid Infinity $275 million up front for rights to duvelisib, and attached a potential $805 million in downstream payments.

Since that time, however, the field of PI3 kinase drugs—and duvelisib—have foundered, surpassed by other approaches. Ibrutinib (Imbruvica), which binds to a different molecular target, has gone on to become a massive-selling drug, and AbbVie shelled out $21 billion for partial rights to it in early 2015. In the meantime, Gilead’s drug has dealt with safety issues, and duvelisib posted disappointing results in a mid-stage trial, leading AbbVie to ditch the partnership and Infinity to cut jobs and close its research operations. And just last week, Genentech sold a PI3 kinase blocker on the verge of Phase 2 trials to Australian biotech Novogen for just $1.6 million up front.

Verastem, meanwhile, is taking a low-cost flier on a drug that at least has a shot at FDA approval. That gives Verastem, a company that has dealt with its own clinical setbacks and currently trades at just $1.27 a share, a chance to generate revenue in the near term if duvelisib comes through. (Infinity, meanwhile, closed at $1.25 a share on Tuesday.)

“While there have been significant advances recently in the treatment of lymphoid malignancies, not all patients experience benefits or can tolerate these treatments,” said Verastem chief medical officer Gregory Berk. “There remains a need for new oral medicines, and the targeted inhibition of PI3K-delta and PI3K-gamma brings a unique approach designed to address both the malignant B cell and its supportive microenvironment.”

Verastem has three other drugs in clinical testing, led by defactinib (VS-6063), which is being tested in combination with immunotherapy drugs pembrolizumab (Keytruda, from Merck) and avelumab (Pfizer/Merck KGaA) in a variety of cancers. Defactinib failed a Phase 2 trial in mesothelioma last year.

The two companies are holding a conference call this morning.

Ben Fidler is Xconomy’s Deputy Biotechnology Editor. You can e-mail him at [email protected] Follow @benthefidler

Trending on Xconomy


Low-cost detachables in the lead as tablet market slump persists – PCMag India

IDC (International Data Corporation) has released a report stating the change in trends in the convertible PC markets.

According to the report, the response for the tablets is still going down. Vendors shipped 43 million units in the third quarter of 2016, a year-over-year decline of 14.7%, according to preliminary data from the International Data Corporation (IDC) Worldwide Quarterly Tablet Tracker.

In contrast to the annual decline, the shipments from the third quarter were up 9.8% over the second quarter of 2016 as the larger vendors prepared for the holiday quarter.

The low cost detachable/convertible machines with a sub-$200 price tag received a considerable rise in sale numbers. However, one of the senior research analyst with IDC, Jitesh Ubrani said,” Unfortunately, many low-cost detachables also deliver a low-cost experience”.

He added, “The race to the bottom is something we have already experienced with slates and it may prove detrimental to the market in the long run as detachables could easily be seen as disposable devices rather than potential PC replacements.”

Even after Apple’s constant promotion for the iPad Pro, the iPad Air and Mini lines have been the models have gotten the most response, resulting for more than two-thirds of its shipments this quarter. Although Apple’s tablet shipments declined 6.2% year over year, total iPad-related revenues were flat for the quarter, thanks to the iPad Pro offering.

Samsung continues to hold the second position. The Note 7 debacle didn’t cause any damage to its tablet segment. It has witnessed an overall decline of 19.3% compared to third quarter of 2015. Samsung’s newest attempt in the convertible market with its latest offering-TabPro S has received a rather timid response because of its uncompetitive position and pricing.

The Amazon Prime Day sale in early July resulted in a considerable hike in shipments of its Fire tablets. The already low-priced device was offered at a 30% discount then, and continued to remain popular throughout the rest of the quarter.

Amazon’s Fire HD 8 which was released recently in October is expected perform well in the holiday quarter, following Amazon’s strategy of selling low-cost tablets to get users into its ecosystem. Lenovo, even with its newer line-up of convertible machines, has seen a 10.8% decline this quarter.


Amedore’s campaign not a low-cost operation – Albany Times Union


For a sign of how fiercely the state Senate’s Republican conference is fighting to maintain its narrow control over the chamber as the clock ticks down to Election Day, consider the 46th District.

The campaign committee of first-term Sen. George Amedore during October received more than $335,000 from the Senate Republican Campaign Committee over the course of three weekly installments.

The Democratic Senate Campaign Committee, meanwhile, spent a comparatively paltry $41,689 to back its candidate, longtime progressive advocate and farmer Sara Niccoli, in the same period.

“We don’t take anything for granted,” said SRCC spokesman Scott Reif. “Having said that, we think Sen. Amedore is going to be re-elected.”

Amedore’s filing for the same period shows more than $454,000 spent on radio and TV ads, including 30-second spots highlighting the lawmaker’s work fighting heroin and opioid addiction and his work on a bill that makes it easier for law enforcement to access abuse records when a child goes missing. That’s almost all of the $469,648 his campaign paid out over that three-week span.

Niccoli’s campaign spent a total of just $18,300 over the same period, the bulk of it on wages for campaign staff and other labor.

Despite the stark resource imbalance, Senate Democratic spokesman Mike Murphy was equally bullish on Niccoli’s candidacy, noting that she “has been out in the communities … speaking with voters and working to address their concerns.”

There have been no publicly released polls in the 46th District, which sweeps from Montgomery County into the suburban parts of Schenectady County, plus suburban and rural Albany County, Greene County and a piece of Ulster County that includes the city of Kingston.

The incumbent’s outlay for on-air ads could be a sign of just how high Republicans are trying to construct a breakwater against a potential blue tidal wave on Tuesday, stirred up in large part by Democratic presidential candidate Hillary Clinton‘s lead over GOP candidate Donald Trump in every credible statewide poll.

Then again, the high price tag could be a function of a district that’s roughly split between a Democrat-leaning southern chunk and a northern zone where Amedore, a well-known local builder, is seen as far stronger. The southern portion, because of its proximity to New York City, also comes with higher media costs: Amedore’s campaign said its TV ad buys in the Capital Region were broadcast and cable; in the southern end of the district, the purchases were cable-only.

Although drawn by the Senate GOP four years ago to add a 63rd seat to the chamber, it was initially won by Duanesburg’s Cecilia Tkaczyk over Amedore — a former Assemblyman — by just 18 votes in 2012, the most recent presidential cycle. The Republican Amedore soundly defeated Tkaczyk in his second try two years later, when his conference managed to retake a clear majority in the Senate.

Elsewhere, the SRCC is following the more familiar playbook of shifting resources from safe candidates to imperiled ones — especially on Long Island and the Lower Hudson Valley, where a host of GOP incumbents are locked in tough races.

According to its October filing, the Senate Democrats‘ campaign committee pumped roughly $310,000 into the campaign of Long Island’s Jim Gaughran, whose race against Sen. Carl Marcellino has been boosted by recent corruption charges laid against two local officials with political ties to the lawmaker.

[email protected]518-454-5619@CaseySeiler


Phillies: Low Cost Closing Pitchers in Free Agency – That Balls Outta Here

Phillies 2016 Closer Jeanmar Gomez (Mandatory Credit: Bill Streicher-USA TODAY Sports)

The Phillies need an upgrade at the closer position heading into 2017. Several low-cost free agent closers are out there on the market.

For a while, it appeared that the Phillies had struck gold with Jeanmar Gomez. Gomez cruised to the All-Star break with 24 saves and a 2.59 ERA. At times, he was actually leading the league in saves.

The remainder of the season was not nice to Gomez, and he got progressively worse as the year went on (8.33 ERA post All-Star). In the end, Gomez’s stats for 2016 – 4.85 ERA, 37-for-43 in save chances, .289 batting average against – make it clear that he shouldn’t  close games.

Is it time for the Phillies to get a new closer? Heck yeah it is.

Closers are certainly low on the priority list for a rebuilding team such as the Phillies, but there’s no reason they can’t sift through the clearance bins. Let’s take a look at some of the free agent relievers that could be closing in Philly next year: